Sana Biotechnology, Inc. Interest Income (Expense), Nonoperating, Net
Sana Biotechnology, Inc. (SANA) reported Interest Income (Expense), Nonoperating, Net of $1.13 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Other Income
us-gaap:InterestIncomeExpenseNonoperatingNet · last filed 2026-08-10
- Sana Biotechnology, Inc. interest income (expense), nonoperating, net for the quarter ending 2026-06-30 was $1.13M, a 95.67% increase year-over-year.
- Sana Biotechnology, Inc. interest income (expense), nonoperating, net for the quarter ending 2026-03-31 was $951.00K, a 4.13% decline year-over-year.
- Sana Biotechnology, Inc. interest income (expense), nonoperating, net for the quarter ending 2025-12-31 was $1.28M, a 22.95% decline year-over-year.
- Sana Biotechnology, Inc. interest income (expense), nonoperating, net for the quarter ending 2025-09-30 was $1.00M, a 61.11% decline year-over-year.
- Sana Biotechnology, Inc. interest income (expense), nonoperating, net for fiscal 2025 was $3.85M, a 63.25% decline from fiscal 2024.
- Sana Biotechnology, Inc. interest income (expense), nonoperating, net for fiscal 2024 was $10.47M, a 5.36% increase from fiscal 2023.
- Sana Biotechnology, Inc. interest income (expense), nonoperating, net for fiscal 2023 was $9.94M, a 164.17% increase from fiscal 2022.
- Sana Biotechnology, Inc. interest income (expense), nonoperating, net for fiscal 2022 was $3.76M, a 456.51% increase from fiscal 2021.
| Period end | Interest Income (Expense), Nonoperating, Net 3 month | Interest Income (Expense), Nonoperating, Net 6 month | Interest Income (Expense), Nonoperating, Net 9 month | Interest Income (Expense), Nonoperating, Net 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.13M 10-Q · filed 2026-08-10 | $2.08M 10-Q · filed 2026-08-10 | $3.36M derived: sum of 3 quarters · filed 2026-08-10 | $4.36M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $951.00K 10-Q · filed 2026-05-11 | $2.23M derived: sum of 2 quarters · filed 2026-05-11 | $3.23M derived: sum of 3 quarters · filed 2026-05-11 | $3.81M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $1.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $2.28M derived: sum of 2 quarters · filed 2026-03-03 | $2.86M derived: sum of 3 quarters · filed 2026-08-10 | $3.85M 10-K · filed 2026-03-03 |
| 2025-09-30 | $1.00M 10-Q · filed 2025-11-06 | $1.58M derived: sum of 2 quarters · filed 2026-08-10 | $2.57M 10-Q · filed 2025-11-06 | $4.23M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $577.00K 10-Q · filed 2026-08-10 | $1.57M 10-Q · filed 2026-08-10 | $3.23M derived: sum of 3 quarters · filed 2026-08-10 | $5.80M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $992.00K 10-Q · filed 2026-05-11 | $2.65M derived: sum of 2 quarters · filed 2026-05-11 | $5.23M derived: sum of 3 quarters · filed 2026-05-11 | $8.43M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $1.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $4.24M derived: sum of 2 quarters · filed 2026-03-03 | $7.44M derived: sum of 3 quarters · filed 2026-03-03 | $10.47M 10-K · filed 2026-03-03 |
| 2024-09-30 | $2.58M 10-Q · filed 2025-11-06 | $5.78M derived: sum of 2 quarters · filed 2025-11-06 | $8.81M 10-Q · filed 2025-11-06 | $11.54M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-06-30 | $3.20M 10-Q · filed 2025-08-11 | $6.24M 10-Q · filed 2025-08-11 | $8.96M derived: sum of 3 quarters · filed 2026-03-03 | $11.82M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-03-31 | $3.03M 10-Q · filed 2025-05-08 | $5.76M derived: sum of 2 quarters · filed 2026-03-03 | $8.62M derived: sum of 3 quarters · filed 2026-03-03 | $11.00M derived: sum of 4 quarters · filed 2026-03-03 |
| 2023-12-31 | $2.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $5.59M derived: sum of 2 quarters · filed 2026-03-03 | $7.96M derived: sum of 3 quarters · filed 2026-03-03 | $9.94M 10-K · filed 2026-03-03 |
| 2023-09-30 | $2.86M 10-Q · filed 2024-11-08 | $5.24M derived: sum of 2 quarters · filed 2024-11-08 | $7.21M 10-Q · filed 2024-11-08 | $8.82M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-06-30 | $2.37M 10-Q · filed 2024-08-08 | $4.35M 10-Q · filed 2024-08-08 | $5.96M derived: sum of 3 quarters · filed 2025-03-17 | $7.14M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-03-31 | $1.98M 10-Q · filed 2024-05-08 | $3.59M derived: sum of 2 quarters · filed 2025-03-17 | $4.76M derived: sum of 3 quarters · filed 2025-03-17 | $5.40M derived: sum of 4 quarters · filed 2025-03-17 |
| 2022-12-31 | $1.61M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $2.79M derived: sum of 2 quarters · filed 2025-03-17 | $3.42M derived: sum of 3 quarters · filed 2025-03-17 | $3.76M 10-K · filed 2025-03-17 |
| 2022-09-30 | $1.17M 10-Q · filed 2023-11-08 | $1.81M derived: sum of 2 quarters · filed 2023-11-08 | $2.15M 10-Q · filed 2023-11-08 | $2.42M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $637.00K 10-Q · filed 2023-08-03 | $976.00K 10-Q · filed 2023-08-03 | $1.24M derived: sum of 3 quarters · filed 2024-02-29 | $1.40M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $339.00K 10-Q · filed 2023-05-08 | $606.00K derived: sum of 2 quarters · filed 2024-02-29 | $764.00K derived: sum of 3 quarters · filed 2024-02-29 | $894.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $267.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $425.00K derived: sum of 2 quarters · filed 2024-02-29 | $555.00K derived: sum of 3 quarters · filed 2024-02-29 | $676.00K 10-K · filed 2024-02-29 |
| 2021-09-30 | $158.00K 10-Q · filed 2022-11-02 | $288.00K derived: sum of 2 quarters · filed 2022-11-02 | $409.00K 10-Q · filed 2022-11-02 | $534.00K derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-06-30 | $130.00K 10-Q · filed 2022-08-04 | $251.00K 10-Q · filed 2022-08-04 | $376.00K derived: sum of 3 quarters · filed 2023-03-16 | $524.00K derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-03-31 | $121.00K 10-Q · filed 2022-05-10 | $246.00K derived: sum of 2 quarters · filed 2023-03-16 | $394.00K derived: sum of 3 quarters · filed 2023-03-16 | $473.00K derived: sum of 4 quarters · filed 2023-03-16 |
| 2020-12-31 | $125.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $273.00K derived: sum of 2 quarters · filed 2023-03-16 | $352.00K derived: sum of 3 quarters · filed 2023-03-16 | $747.00K 10-K · filed 2023-03-16 |
| 2020-09-30 | $148.00K 10-Q · filed 2021-11-08 | $227.00K derived: sum of 2 quarters · filed 2021-11-08 | $622.00K 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $79.00K 10-Q · filed 2021-08-04 | $474.00K 10-Q · filed 2021-08-04 | ||
| 2020-03-31 | $395.00K 10-Q · filed 2021-05-05 | |||
| 2019-12-31 | $2.86M 10-K · filed 2022-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |